Anzurstobart

DB17547InvestigationalProtein Based Therapies

Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction. It is being investigated for cancers.

Mechanism: Pharmacologically active on Tyrosine-protein phosphatase non-receptor type substrate 1
Curator reviewed
Code names: BMS-986351 · CC-95251

Resolves to

Compound

UNII61FKP5V847CAS2543693-10-1

Targets

P78324SIRPA

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Anzurstobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account